Harrow Announces First Quarter 2025 Revenue Growth
Published on May 12, 2025
NASHVILLE, Tenn.—Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, has announced results for the first quarter ended March 31, 2025. The company reported revenue of $47.8 million for the first quarter of 2025, a 38 percent increase compared with $34.6 million in the prior-year period. Vevye revenues grew to $21.5 million, a 35 percent increase from $16.0 million in the fourth quarter of 2024. Vevye (cyclosporine ophthalmic solution) 0.1% is a prescription drop used to treat the signs and symptoms of dry eye disease